A Limulus antilipopolysaccharide factor-derived peptide exhibits a new immunological activity with potential applicability in infectious diseases

Clinical and Diagnostic Laboratory Immunology

Volumn 7, Issue 4, 2000, Pages 669-675

  Vallespi, Maribel G ^a   Glaria, Luis A ^a   Reyes, Osvaldo ^b   Garay, Hilda E ^b   Ferrero, Joel ^b   Araña, Manuel J ^a  

^a Center for Biological Research Cuba   (Cuba)

^b CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT; LIMULUS ANTILIPOPOLYSACCHARIDE FACTOR; NITRIC OXIDE; PEPTIDE DERIVATIVE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOREACTIVITY; MACROPHAGE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-INFECTIVE AGENTS; HORSESHOE CRABS; HUMANS; INVERTEBRATE HORMONES; LIPOPOLYSACCHARIDES; MICE; PEPTIDES;

EID: 0033941532     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.7.4.669-675.2000     Document Type: Article

References (51)

1. Ammons, W. S., F. R. Kohn, and A. H. Kung. 1994. Protective effects of an N-terminal fragment of bactericidal/permeability-increasing protein in rodent models of Gram-negative sepsis: role of bactericidal properties. J. Infect. Dis. 170:1473-1482.
2. Battafarano, R. J., P. S. Dahlberg, and C. A. Ratz. 1995. Peptide derivatives of three distinct lipopolysaccharide binding proteins inhibit lipopolysaccharide-induced TNF secretion in vitro. Surgery 118:318-324.
3. Browder, W., D. Williams, H. Pretus, G. Olivero, F. Enrichens, P. Mao, and A. Franchello. 1990. Beneficial effect of enhanced macrophage function in the trauma patient. Ann. Surg. 211:605-613.
4. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
5. Dent, A. L., Y. X. Shaffer, D. Allman, and L. M. Staudt. 1997. Cytokine expression and germinal center formation by Bcl-2. Science 276:589-592.
6. Dentener, M. A., V. Bazil, E. J. Von Asmuth, and M. Ceska. 1993. Involvement of CD14 in lipopolysaccharide-induced tumor necrosis factor, IL-6 and IL-8 release by human monocytes and alveolar macrophages. J. Immunol. 150:2885-2891.
7. Döcke, W. D., U. Syrbe, A. Meinicke, C. Platzer, A. Makki, K. Asadullah, C. Klug, H. Zuckermann, P. Reinke, H. Brunner, R. Von Baehr, and H. D. Volk. 1994. Improvement of monocytic function: a new therapeutic approach in sepsis? p. 473-488. In Reinhart (ed.), Update in intensive care and emergency medicine - 1994. Springer, Berlin, Germany.
8. Elliott, M. J., R. N. Maini, M. Feldmann, J. R. Kalden, C. Antoni, and J. S. Smolen. 1994. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105-1110.
9. Ertel, W., M. H. Morrison, P. Wang, Z. F. Ba, A. Ayala, and I. H. Chaudry. 1991. The complex pattern of cytokines in sepsis. Association between prostaglandins, cachectin, and interleukins. Ann. Surg. 214:141-148.
10. Famillietti, P. C., S. Rubinstein, and S. Pestka. 1981. Assay of interferon activity. Methods Enzymol. 78:387-396.
11. Felippe, J., M. Silva, and F. M. Maciel. 1993. Infection prevention in patients with severe multiple trauma with the immunomodulator beta 1-3 polyglucose (glucan). Surg. Gynecol. Obstet. 177:383-388.
12. Ferrero, J., M. E. Ochagavia, and A. Aguilera. 1994. Titulación de la actividad antiviral de interferones utilizando el sistema de equipes SUMA. Biotechnol. Apl. 11:25-30.
13. Fletcher, M. A., M. A. Kloczewiak, P. M. Loiselle, M. Ogata, M. W. Vermeulen, E. M. Zanzot, and H. S. Warren. 1997. A novel peptide-IgG conjugate, Cap-18-IgG, that binds and neutralizes endotoxin and kills gram-negative bacteria. J. Infect. Dis. 175:621-632.
14. Fujiwara, H., J. P. Zou, S. Herrmann, and T. Hamaoka. 1995. A sequence of cellular and molecular events involved in IL-12-induced tumor regression. Res. Immunol. 6:638-644.
15. Gabbai, F. B., C. Boggiano, T. Peter, S. Khang, C. Archer, D. P. Gold, and C. J. Kelly. 1998. Inhibition of inducible nitric oxide synthase intensifies injury and functional deterioration in autoimmune interstitial nephritis. J. Immunol. 159:6266-6275.
16. Gilman, M. 1998. In Current protocols in molecular biology, p. 4.7.1-4.7.8. John Wiley and Sons, New York, N.Y.
17. Goris, R. J. A. 1993. Sepsis and multiple organ failure: the result of whole body inflammation, p. 161-170. In E. Faist. J. Meakins, and F. W. Schildberg (ed.), Host defense dysfunction in trauma, shock and sepsis. Springer-Verlag, Berlin, Germany.
18. Groote, M. A., M. A. Martin, P. Densen, M. Pfaller, and R. P. Wenzel. 1989. Plasma tumor necrosis factor levels in patients with presumed sepsis. Results in those treated with antilipid A antibody versus placebo. JAMA 262:249-251.
19. Hagen, T. L., W. van Vianen, H. F. Savelkoul, H. Heremans, W. A. Buurman, and I. A. Bakker-Woudenberg. 1998. Involvement of T cells in enhanced resistance to Klebsiella pneumoniae septicemia in mice treated with liposome-encapsulated muramyl tripeptide phosphatidylethanolamine or gamma interferon. Infect. Immun. 66:1962-1967.
20. Hartung, T., W. D. Doecke, and F. Gantner. 1995. Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood 85:2482-2489.
21. Hirata, M., J. Zhong, S. C. Wright, and J. W. Larrick. 1997. Structure and functions of endotoxin-binding peptides derived from Cap-18. Prog. Clin. Biol. Res. 392:317-326.
22. Hoess, A., S. Watson, G. R. Siber, and R. Liddington. 1993. Crystal structure of an endotoxin-neutralizing protein from the horseshoe crab. Limulus anti-LPS factor, at 1.5 Å resolution. EMBO J. 112:3351-3356.
23. Jakobsen, P. H., C. Koch, and K. Bendtzen. 1997. Inhibition of LPS and Plasmodium falciparum induced cytokine secretion by pentoxifylline and two analogues. Scand. J. Immunol. 45:545-550.
24. Jilg, S., J. Barsig, and M. Leist. 1996. Enhanced release of interleukin-10 and soluble tumor necrosis factor receptors as novel principles of methylxanthine action in murine models of endotoxin shock. J. Pharmacol. Exp. Ther. 278:421-431.
25. Jones, A. L., and P. Selby. 1989. Tumor necrosis factor: clinical relevance. Cancer Surv. 8:817.
26. Klareskog, J., J. Rönnelid. and G. Holm. 1995. Immunopathogenesis and immunotherapy in rheumatoid arthritis: an area in transition. J. Intern. Med. 238:191-206.
27. Kloczewiak, M., K. M. Black, P. Loiselle, J. M. Cavaillon, N. Wainwright, and H. S. Warren. 1994. Synthetic peptides that mimic the binding site of horseshoe crab antilipopolysaccharide factor. J. Infect. Dis. 170:1490-1497.
28. Leist, M., F. Gantner, S. Jilg, and A. Wendel. 1995. Activation of the 55 kDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release. J. Immunol. 154:1307-1316.
29. Mathison, J. C., E. Wolfson, and R. Ulevitch. 1988. Participation of tumor necrosis factor in the mediation of gram-negative bacterial lipopolysaccharide-induced injury in rabbits. J. Clin. Investig. 81:1925.
30. Morita, T., S. Ohtsubo, and T. Nakamura. 1985. Isolation and biological activities of Limulus anticoagulant (anti-LPS factor) which interact with lipopolysaccharide (LPS). J. Biochem. 97:1611-1620.
31. Mosmann, T. R., and S. Sad. 1996. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 17:138-148.
32. Natanson, C., W. D. Hoffman, A. F. Suffredini, P. Q. Eichacker, and R. L. Danner. 1994. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann. Intern. Med. 120:771-783.
33. Nathan, J. F., C. Radzioch, and A. Ding. 1997. Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell 88:417-426.
34. 2. Immunobiology 184:93-105.
35. Nussler, A., J. C. Drapier, L. Renia, S. Pied, F. Miltgen, M. Gentilini, and D. Mazier. 1991. L-Arginine-dependent destruction of intrahepatic malaria parasites in response to TNF and/or IL-6 stimulation. Eur. J. Immunol. 21:227-230.
36. Ried, C., C. Wahl, T. Miethke, G. Wellnhofer, C. Landgraf, J. Schneider-Mergener, and A. Hoess. 1996. High affinity endotoxin-binding and neutralizing peptides based on the crystal structure of recombinant Limulus anti-LPS factor. J. Biol. Chem. 271:28120-28127.
37. Robert, I. R., S. Donghui, A. H. Child, N. R. Wainwright, and J. Levin. 1998. Limulus antilipopolysaccharide factor prevents mortality late in the course of endotoxemia. J. Infect. Dis. 177:388-394.
38. Schumann, R. R., N. Lamping, and A. Hoess. 1997. Interchangeable endotoxin-binding domains in proteins with opposite lipopolysaccharide-dependent activities. J. Immunol. 159:5599-5605.
39. Seatter, S. C., T. Bennet, and M. H. Li. 1994. Macrophage endotoxin tolerance: tumor necrosis factor and interleukin-1 regulation by lipopolysaccharide pretreatment. Arch. Surg. 129:1263-1270.
40. Sinha, B., J. Semmler, and T. Eisenhut. 1995. Enhanced tumor necrosis factor suppression and cycle adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur. J. Immunol. 25:147-153.
41. Srimal, S., N. Surolia, S. Balasubramanian, and A. Surolia. 1996. Titration calorimetric studies to elucidate the specificity of the interactions of polymyxin B with LPS and lipid A. Biochem. J. 315:679-686.
42. Steege, J. C., M. W. van de Ven, P. P. Forget, P. Brouckaert, and W. A. Buurman. 1998. The role of endogenous IFN-gamma, TNF-alpha and IL-10 in LPS-induced nitric oxide release in a mouse model. Cytokine 10:115-123.
43. Szabo, C., J. A. Mitchell, S. S. Gross, C. Thiemermann, and J. R. Vane. 1992. Nifedipine inhibits the induction of nitric oxide synthase by bacterial lipopolysaccharide. J. Pharmacol. Exp. Ther. 265:674-680.
44. Taylor, A. H., G. Heavner, M. Nedelman, D. Sherris, E. Brunt, D. Knight, and J. Ghrayed. 1995. Lipopolysaccharide (LPS) neutralizing peptides reveal a lipid A binding site of LPS binding protein. J. Biol. Chem. 270:17934-17938.
45. Volk, H. D., P. Reinke, D. Krausch, H. Zuckermann, K. Asadullah, J. M. Muller, W. D. Docke, and W. J. Kox. 1996. Monocyte deactivation - rationale for a new therapeutic strategy in sepsis. Intensive Care Med. 22:S474-S481.
46. Warren, H. S., M. L. Glennon, and N. Wainwright. 1992. Binding and neutralization of endotoxin by Limulus antilipopolysaccharide factor. Infect. Immun. 60:2506-2513.
47. Welbourn, C. R., and Y. Young. 1992. Endotoxin, septic shock and acute lung injury: neutrophils, macrophages and inflammatory mediators. Br. J. Surg. 79:998-1003.
48. Williams, D. L., A. Mueller, and W. Browder. 1996. Glucan-based macrophage stimulators. Clin. Immunother. 5:392-399.
49. Woo, P. 1997. The cytokine network in juvenile chronic arthritis. Pediatr. Rheumatol. 23:491-498.
50. Xie, Q. W., R. Whisnant, and C. Nathan. 1993. Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by IFN-γ and bacterial lipopolysaccharide. J. Exp. Med. 177:1779-1784.
51. Zoltan, H., H. György, C. Szabo, and E. S. Vizi. 1997. Amrinone and theophylline differentially regulate cytokine and nitric oxide production in endotoxemic mice. Shock 7:371-375.